Thromboembolic risk with IVIg: Incidence and risk factors in patients with inflammatory neuropathy.


Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
11 02 2020
Historique:
received: 10 01 2019
accepted: 15 08 2019
pubmed: 20 12 2019
medline: 19 5 2020
entrez: 20 12 2019
Statut: ppublish

Résumé

Our objective was to evaluate whether IV immunoglobulin (IVIg) increases the risk of thromboembolic events in neurology outpatients with inflammatory neuropathies, as there is conflicting evidence supporting this hypothesis, mainly from non-neurologic cohorts. We investigated this question over 30 months in our cohort of patients with inflammatory neuropathies receiving regular IVIg and found a greater incidence of arterial and venous thromboembolic events than population-based rates determined by hospital admissions data. Vascular risk factors were more common in the event group but there were no IVIg administration factors that contributed to the risk. This study suggests that IVIg may have a small but contributory role in determining thromboembolic risk in the inflammatory neuropathy cohort and more evidence is required before it is clear whether the current primary prevention guidelines are appropriate in this group of patients.

Identifiants

pubmed: 31852814
pii: WNL.0000000000008742
doi: 10.1212/WNL.0000000000008742
pmc: PMC7136065
doi:

Substances chimiques

Immunoglobulins, Intravenous 0
Immunologic Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e635-e638

Informations de copyright

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Références

Clin Exp Immunol. 2014 Dec;178 Suppl 1:153-5
pubmed: 25546802
Lancet. 1986 Jul 26;2(8500):217-8
pubmed: 2873457
Blood. 2016 Jan 14;127(2):200-7
pubmed: 26443622
J Neurol Sci. 2011 Sep 15;308(1-2):124-7
pubmed: 21679973
Br J Gen Pract. 2017 Dec;67(665):e881-e887
pubmed: 29061715
N Engl J Med. 2001 Sep 6;345(10):747-55
pubmed: 11547745

Auteurs

Mahima Kapoor (M)

From the National Hospital of Neurology and Neurosurgery (J.S., C.E., S.S.-G., M.P.L., A.C.); MRC Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases (M.K., A.R., H.M., M.M.R.), UCL Institute of Neurology; Department of Cardiology (R.B.), University College London Hospital; and Department of Neuroimmunology (M.P.L.), Institute of Neurology, London, UK.

Jennifer Spillane (J)

From the National Hospital of Neurology and Neurosurgery (J.S., C.E., S.S.-G., M.P.L., A.C.); MRC Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases (M.K., A.R., H.M., M.M.R.), UCL Institute of Neurology; Department of Cardiology (R.B.), University College London Hospital; and Department of Neuroimmunology (M.P.L.), Institute of Neurology, London, UK.

Christina Englezou (C)

From the National Hospital of Neurology and Neurosurgery (J.S., C.E., S.S.-G., M.P.L., A.C.); MRC Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases (M.K., A.R., H.M., M.M.R.), UCL Institute of Neurology; Department of Cardiology (R.B.), University College London Hospital; and Department of Neuroimmunology (M.P.L.), Institute of Neurology, London, UK.

Scherezade Sarri-Gonzalez (S)

From the National Hospital of Neurology and Neurosurgery (J.S., C.E., S.S.-G., M.P.L., A.C.); MRC Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases (M.K., A.R., H.M., M.M.R.), UCL Institute of Neurology; Department of Cardiology (R.B.), University College London Hospital; and Department of Neuroimmunology (M.P.L.), Institute of Neurology, London, UK.

Robert Bell (R)

From the National Hospital of Neurology and Neurosurgery (J.S., C.E., S.S.-G., M.P.L., A.C.); MRC Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases (M.K., A.R., H.M., M.M.R.), UCL Institute of Neurology; Department of Cardiology (R.B.), University College London Hospital; and Department of Neuroimmunology (M.P.L.), Institute of Neurology, London, UK.

Alexander Rossor (A)

From the National Hospital of Neurology and Neurosurgery (J.S., C.E., S.S.-G., M.P.L., A.C.); MRC Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases (M.K., A.R., H.M., M.M.R.), UCL Institute of Neurology; Department of Cardiology (R.B.), University College London Hospital; and Department of Neuroimmunology (M.P.L.), Institute of Neurology, London, UK.

Hadi Manji (H)

From the National Hospital of Neurology and Neurosurgery (J.S., C.E., S.S.-G., M.P.L., A.C.); MRC Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases (M.K., A.R., H.M., M.M.R.), UCL Institute of Neurology; Department of Cardiology (R.B.), University College London Hospital; and Department of Neuroimmunology (M.P.L.), Institute of Neurology, London, UK.

Mary M Reilly (MM)

From the National Hospital of Neurology and Neurosurgery (J.S., C.E., S.S.-G., M.P.L., A.C.); MRC Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases (M.K., A.R., H.M., M.M.R.), UCL Institute of Neurology; Department of Cardiology (R.B.), University College London Hospital; and Department of Neuroimmunology (M.P.L.), Institute of Neurology, London, UK.

Michael P Lunn (MP)

From the National Hospital of Neurology and Neurosurgery (J.S., C.E., S.S.-G., M.P.L., A.C.); MRC Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases (M.K., A.R., H.M., M.M.R.), UCL Institute of Neurology; Department of Cardiology (R.B.), University College London Hospital; and Department of Neuroimmunology (M.P.L.), Institute of Neurology, London, UK.

Aisling Carr (A)

From the National Hospital of Neurology and Neurosurgery (J.S., C.E., S.S.-G., M.P.L., A.C.); MRC Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases (M.K., A.R., H.M., M.M.R.), UCL Institute of Neurology; Department of Cardiology (R.B.), University College London Hospital; and Department of Neuroimmunology (M.P.L.), Institute of Neurology, London, UK. aisling.carr@nhs.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH